Recent advances in molecular biology have provided unprecedented insights into the structure of amyloid fibrils associated ...

The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability.

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...

thh.nhs.uk The amyloidoses are a group of diseases in which amyloid, a proteinaceous substance, deposits in one or more organs. As many as 23 different precursor proteins to the formation of amyloid ...

In the second part, we cover several of our footprinting applications for the study of biotherapeutics, metal-bound proteins, aggregating (amyloid) proteins, and integral membrane proteins (IMPs).

A new study that provides a multipronged approach to treatment of several neurodegenerative diseases, offers hope for Alzheimer’s Disease, Dementia, and related diseases.Amyloid proteins and peptides ...

The revised criteria offer guidance for clinicians to determine when amyloid and tau PET are recommended. Criteria were divided into 17 common clinical scenarios with three subcategories of ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

The kinetics of fibrillization in dilute aqueous solutions of the protein was monitored as a function of incubation time using the dye thioflavin T, which binds to amyloid fibrils but not to ...

The search for answers to Alzheimer's disease and other neurodegenerative disorders remains one of the most pressing goals in ...

This manuscript describes the identification and characterization of 12 specific phosphomimetic mutations in the recombinant full-length human tau protein that trigger tau to form fibrils. This ...